Shots:

• In terms of the agreement- lilly will commercialize the system- which is currently in development & will include an insulin pump developed & manufactured by ypsomed
• Ypsomed's insulin pump has been marketed in europe since 2016- available in 21 countries as the mylife ypsopump. Lilly will commercialize a version of this insulin pump- along with CGM & automated insulin delivery technology- in the US & europe also this pump will use pre-filled insulin cartridges for Lilly's rapid-acting insulins
• Ypsomed plans to submit a version of the mylife ypsopump for clearance to the US FDA for use in automated insulin delivery in 2022- if cleared- lilly will have exclusive rights to commercialize the pump in the US

 ­ Ref: Lilly | Image: Lilly